Belzutifan Eligible Von Hippel Lindau Disease Associated Renal Cell Carcinoma Therapeutics
1. Welireg patent expiration
Treatment: Treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand inhibitor and a vascular endothelial growth factor tyrosine kinase inh...
Can you believe WELIREG received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9969689 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(8 years from now) | |
| US9908845 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(8 years from now) | |
| USRE49948 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12358870 | MERCK SHARP DOHME | NA |
Jun, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2026 |
| New Indication(I-931) | Dec 14, 2026 |
| New Indication(I-968) | May 14, 2028 |
| Orphan Drug Exclusivity(ODE-364) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 13 August, 2025
Market Authorisation Date: 13 August, 2021
Dosage: TABLET
More Information on Dosage
WELIREG family patents
